Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia in Europe, a Real-World Perspective
Nov 13, 2018
To date, there are no robust head-to-head comparisons of tyrosine kinase inhibitors (TKIs) regarding treatment flow in chronic myeloid leukaemia (CML). The available evidence is limited to observational studies of small size. This study aims to understand treatment patterns of TKIs and relevant side effects in CML
You may also be interested in
Contact Us
Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.